Regulatory Affairs Specialists

Specialized AI platforms are in active commercial deployment specifically targeting the core workflow of regulatory affairs professionals — eCTD/CTD compilation, clinical summary narrative generation, and module drafting. Veeva Vault AI (launched 2023) is deployed across 15 of the top 20 pharma companies for document automation. Inari, a purpose-built regulatory AI company, raised $15M in 2023 specifically for submission automation. Pharma companies including AstraZeneca, Pfizer, and Sanofi have disclosed internal LLM deployment programs that generate first-draft submission content from structured clinical data. This is not a future risk scenario — it is an active market with paying customers and measurable time savings already being reported.

GPT-4-class and Claude-class LLMs have been evaluated against junior-to-mid-level regulatory affairs specialists on regulatory guidance interpretation tasks — parsing ICH guidelines, applying FDA guidance to novel product scenarios, and identifying applicable EMA scientific advice — and consistently perform at or above the junior specialist benchmark. These models have ingested the complete publicly available corpus of regulatory guidance documents, agency meeting minutes, published assessment reports, and regulatory science literature. The knowledge arbitrage that made junior and mid-level regulatory specialists economically valuable — 'I know the guidance and how agencies interpret it' — is eroding. Regulatory consultancies including Halloran, Regulatory Compliance Associates, and Charles River Regulatory Sciences have disclosed internal evaluations confirming this competency overlap.